If you searched Leap Therapeutics and landed here expecting a straightforward biotech stock profile, the honest answer is more interesting than that. The company most people know as Leap Therapeutics does not trade under that name anymore. It renamed itself Cypherpunk Technologies in November 2025 and pivoted a chunk of its balance sheet into Zcash, the privacy focused cryptocurrency, while quietly keeping its cancer drug programs alive through a subsidiary. A lot of what still ranks on Google for this exact keyword has not caught up with that change, which is exactly the gap this article fills.
Who Leap Therapeutics Was Before The Pivot
Leap Therapeutics started as a Cambridge, Massachusetts biotechnology company trading on Nasdaq under the ticker LPTX, developing targeted and immuno oncology therapeutics. Its most advanced program was sirexatamab, formerly known as DKN-01, a monoclonal antibody targeting a protein called DKK1 that plays a role in the Wnt signaling pathway implicated in several cancers. A second candidate, FL-501, targeted GDF-15. The company ran trials across esophagogastric, hepatobiliary, gynecologic, and prostate cancers, and at various points held partnerships tied to its pipeline, including licensing arrangements connected to BeiGene. Through 2019, Leap raised capital through multiple public offerings and private placements, a fairly ordinary path for a small clinical stage biotech burning cash on trials with no approved product yet generating revenue.
By 2025, the picture had turned difficult. Reporting on the transition describes Leap winding down its cancer drug programs earlier in the year, with sirexatamab struggling to secure further funding in a tight biotech financing environment. Plenty of small cap oncology names hit this wall. What happened next is the part that makes this company worth a fresh look.
The Rebrand To Cypherpunk Technologies, Explained
On November 12, 2025, Leap Therapeutics announced it would change its name to Cypherpunk Technologies Inc. and unveiled a digital asset treasury strategy built around accumulating ZEC, the native coin of the Zcash network. The company began trading under the new ticker CYPH on November 13, 2025. This was not a small side bet. Cypherpunk had just closed a $58.88 million private placement led by Winklevoss Capital, the investment firm run by Cameron and Tyler Winklevoss, and Winklevoss Capital was the sole institutional investor behind the round, contributing the bulk of the total raised.
Cypherpunk moved fast with the money. It used $50 million of the proceeds to buy 203,775.27 ZEC at an average price of roughly $245 per coin, and the company has stated a goal of eventually holding as much as 5% of Zcash’s total circulating supply, which sits around 16 to 17 million coins against a fixed maximum of 21 million, the same hard cap structure Bitcoin uses. Reporting from StockTitan later in the same cycle noted an additional purchase of just over 56,000 ZEC for roughly 29 million dollars at a higher average price near 514 dollars per coin, pushing total holdings above 290,000 ZEC at a blended average cost near 334 dollars per coin, a figure representing close to 1.76% of circulating supply at the time.
Leadership changed alongside the name. Khing Oei, previously the founder of a Bitcoin treasury firm called Treasury and a veteran of the digital asset investing space, became Chairman of the Board. Will McEvoy, a Principal at Winklevoss Capital, was named the company’s first ever Chief Investment Officer. Christopher Mirabelli, who had chaired the board through the biotech era, stepped down from that role but remained a board member, which is a detail worth noting since it shows the oncology side was not simply discarded in the transition.
Why Zcash Specifically, And What The Company Says About It
Zcash launched in 2016 as a fork of Bitcoin’s codebase, and its defining feature is the use of zero knowledge proofs, specifically a technique called zk-SNARKs, which let the network verify a transaction is valid without revealing the sender, receiver, or amount involved. You can read the deeper cryptographic history of the underlying privacy technology on Wikipedia’s Zcash entry. Tyler Winklevoss has publicly framed Zcash as an “encrypted” counterpart to Bitcoin, describing the two as complementary rather than competing assets, and Cypherpunk’s own materials describe privacy as a shrinking resource in an increasingly digitized financial system.
Whether that framing holds up is genuinely a matter of debate, and this article is not going to pretend otherwise. Privacy coins have historically faced tougher regulatory scrutiny than Bitcoin or Ethereum precisely because their transaction details are harder to trace, and several exchanges have delisted privacy coins in specific jurisdictions over the years in response to anti money laundering pressure. Betting a public company’s treasury on a privacy coin is a different risk profile than betting on Bitcoin, and investors weighing Cypherpunk should treat that as a real consideration rather than a footnote. Regulatory posture toward privacy coins also varies a lot by country, and a rule change in one major market can move sentiment on Zcash specifically in a way that would not necessarily touch Bitcoin, since Bitcoin’s transaction transparency is precisely what regulators tend to view as lower risk.
Read More : Why Is XRP Dropping? The Real Reasons Behind the 2026 Slide
What Happened To The Oncology Pipeline
The cancer research did not disappear, and this is a detail plenty of the crypto focused coverage glosses over. Cypherpunk’s own press materials state it continues developing sirexatamab and FL-501 through a wholly owned subsidiary that retains the Leap Therapeutics name. Company disclosures have referenced Phase 2 data for sirexatamab in colorectal cancer patients showing a meaningful difference in outcomes for patients with high DKK1 levels compared to those with low levels, based on measures like objective response rate and median progression free survival. None of that changes the fact that the company’s primary strategic identity and treasury allocation have shifted decisively toward digital assets, but it does mean the biotech story is not entirely over, just demoted from headline to subplot.
Reading The Stock History Honestly
LPTX traded in a wide and often rough range through 2025, reflecting the kind of volatility typical of a small cap clinical stage biotech without approved products generating revenue. Once the Cypherpunk rebrand and Zcash treasury news hit, the stock moved sharply, with contemporaneous reporting describing an intraday jump of more than 100% around the announcement. Since then, CYPH has traded with the kind of volatility you would expect from a stock whose value is now closely tied to a single, historically volatile cryptocurrency rather than diversified clinical trial outcomes. This is exactly the kind of situation where checking a live, current stock quote matters more than trusting any number in an article, since digital asset treasury companies can swing meaningfully in a single trading session based on the underlying coin’s price alone.
A useful way to think about this model, since it is not unique to Cypherpunk, is to compare it to how other public companies have used a similar playbook of holding a specific cryptocurrency on the balance sheet as a core strategy rather than a side investment. That structure concentrates a shareholder’s exposure to one asset’s price swings inside what used to be a diversified operating business, and it is worth understanding that tradeoff clearly before assuming the stock behaves like a typical biotech or a typical crypto fund.
A Clear Timeline Of What Happened And When
Laying out the dates in one place clears up more confusion than any narrative explanation, since a lot of the search results for this keyword mix up the order of events. Through 2017 to 2019, Leap Therapeutics raised capital through several public offerings and private placements while advancing sirexatamab and its earlier programs, standard fundraising for a clinical stage biotech. Earlier in 2025, the company wound down active cancer drug development as funding for sirexatamab became difficult to secure in a tightening biotech financing market. In October 2025, Cypherpunk closed a $58.88 million private placement led by Winklevoss Capital. On November 11, 2025, the company appointed Khing Oei as Chairman and Will McEvoy as Chief Investment Officer, with Christopher Mirabelli stepping down as chair but staying on the board. On November 12, 2025, the company announced its new name and Zcash treasury strategy, and on November 13, 2025, it began trading as CYPH. A special stockholder meeting followed on December 15, 2025, to formally vote on matters tied to the strategic shift. By December 19, 2025, the company had named Josh Swihart, CEO of Electric Coin Company, as a strategic advisor to guide its Zcash ecosystem strategy specifically.
If You Held LPTX Shares Before The Pivot
Anyone who bought Leap Therapeutics as a biotech play and is now looking at a stock called Cypherpunk on their brokerage statement is not looking at a mistake or a glitch. The underlying legal entity, share count, and CUSIP typically carry over through this kind of name and ticker change, meaning existing shareholders became Cypherpunk shareholders automatically rather than needing to take any action, though the specific mechanics of any given brokerage’s handling of a ticker change are worth confirming directly with that broker rather than assuming. What did change completely is the investment thesis. A person who bought LPTX for its oncology pipeline is now holding a stock whose value is driven primarily by Zcash’s price and the market’s read on this treasury strategy, not by trial results. That is a fundamentally different bet than the one originally made, even though technically it is the same shares.
Where To Verify Current Numbers Before You Do Anything
Every number in this article, ZEC holdings, average purchase price, stock price, and percentage of circulating supply, moves regularly, sometimes within days. Before making any financial decision, check the company’s own investor relations page and its SEC filings directly, since press coverage and secondary sources can lag official disclosures by days or weeks. Treasury companies built around a single volatile asset are exactly the kind of situation where a stale number from an old article can lead someone to a badly outdated picture of the actual risk they would be taking on.
Common Questions People Actually Have
People searching this keyword tend to land in one of two buckets. Some are old biotech investors trying to figure out what happened to a stock they used to hold and why it now shows a totally different ticker and business description on their brokerage app. Others are crypto focused readers who heard about Cypherpunk’s Zcash treasury and are working backward to understand its biotech origin. Both groups deserve the same honest starting point: this is now a digital asset treasury company with a legacy oncology subsidiary attached, not the reverse.
Frequently Asked Questions
Is Leap Therapeutics still a biotech company.
Not primarily. It renamed itself Cypherpunk Technologies in November 2025 and now focuses on a Zcash digital asset treasury strategy, while its original cancer drug programs continue through a subsidiary that kept the Leap Therapeutics name.
What is the new ticker symbol for Leap Therapeutics.
The stock trades on Nasdaq as CYPH as of November 13, 2025, replacing the former ticker LPTX.
Why did Leap Therapeutics pivot to Zcash.
The company’s leadership, backed by a $58.88 million private placement led by Winklevoss Capital, stated a belief that privacy focused digital assets represent a long term strategic opportunity, framing Zcash as a complement to Bitcoin.
Did Leap Therapeutics abandon its cancer drug research.
No, the company continues developing sirexatamab and FL-501 through a wholly owned subsidiary that retained the Leap Therapeutics name, even though the parent company’s primary strategic focus has shifted to digital assets.
Who is behind the Cypherpunk Zcash treasury strategy.
Winklevoss Capital, the investment firm led by Cameron and Tyler Winklevoss, was the sole institutional investor in the private placement that funded the strategy, and Winklevoss Capital Principal Will McEvoy now serves as Cypherpunk’s Chief Investment Officer.
Is investing in a digital asset treasury company like Cypherpunk risky.
Yes, this model concentrates shareholder exposure to a single cryptocurrency’s price movements inside what used to be a diversified operating business, which is a materially different risk profile than either a typical biotech stock or a typical crypto fund, and this article is not a recommendation either way.
